Scarica l'app Stockscreener
9.00
7.14%
0.60
Pre-mercato:
9.00
Precedente Chiudi:
$8.40
Aprire:
$8.7
Volume 24 ore:
414.75K
Relative Volume:
2.39
Capitalizzazione di mercato:
$192.40M
Reddito:
$66.59M
Utile/perdita netta:
$-104.93M
Rapporto P/E:
-1.8182
EPS:
-4.95
Flusso di cassa netto:
$-96.48M
1 W Prestazione:
+4.05%
1M Prestazione:
+26.58%
6M Prestazione:
+15.68%
1 anno Prestazione:
-30.12%
Intervallo 1D:
$8.33
$9.17
Intervallo di 1 settimana:
$8.33
$9.17
Portata 52W:
$4.09
$13.37
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Nome
Enanta Pharmaceuticals Inc
Settore
Industria
Telefono
617 607 0800
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Confronta ENTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
9.00 | 179.57M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2023-08-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Iniziato | Evercore ISI | Underperform |
| 2020-08-28 | Ripresa | ROTH Capital | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-27 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Iniziato | Wolfe Research | Outperform |
| 2019-04-23 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-12-13 | Iniziato | Berenberg | Hold |
| 2018-06-06 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-11 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | Barclays | Underweight |
| 2015-10-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
Mostra tutto
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial a - PharmiWeb.com
Live market analysis of Enanta Pharmaceuticals Inc.Portfolio Profit Report & Weekly Stock Performance Updates - Newser
Enanta Pharmaceuticals announces passing of longtime CFO Paul Mellett - Investing.com
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
Enanta Pharmaceuticals: Leadership Continuity and Strategic Resilience in Biotech R&D - AInvest
Enanta Pharmaceuticals Receives New 'Buy' Rating from WestPark Capital with $24.00 Price Target - AInvest
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Announces Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr. - AInvest
Two Decades of Leadership: Enanta Pharmaceuticals Mourns Loss of CFO Who Helped Cure 1M+ HCV Patients - Stock Titan
How to build a custom watchlist for Enanta Pharmaceuticals Inc.July 2025 Big Picture & Technical Pattern Recognition Alerts - Newser
Historical volatility pattern of Enanta Pharmaceuticals Inc. visualizedTrade Entry Report & Short-Term Trading Opportunity Alerts - Newser
Measuring Enanta Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - Newser
Published on: 2025-09-03 03:49:04 - Newser
Short interest data insights for Enanta Pharmaceuticals Inc.Insider Selling & Precise Buy Zone Tips - Newser
How to build a dashboard for Enanta Pharmaceuticals Inc. stockJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
Using data filters to optimize entry into Enanta Pharmaceuticals Inc.Index Update & Technical Pattern Based Buy Signals - Newser
Can you recover from losses in Enanta Pharmaceuticals Inc.2025 Investor Takeaways & Expert Approved Trade Ideas - Newser
Real time social sentiment graph for Enanta Pharmaceuticals Inc.Trend Reversal & Accurate Entry/Exit Alerts - Newser
Is Enanta Pharmaceuticals Inc. reversing from oversold territory2025 Technical Patterns & AI Driven Price Predictions - Newser
Key resistance and support levels for Enanta Pharmaceuticals Inc.July 2025 Short Interest & Long-Term Growth Plans - Newser
Is Enanta Pharmaceuticals Inc. forming a breakout patternJuly 2025 Movers & Technical Buy Zone Confirmations - خودرو بانک
What’s the outlook for Enanta Pharmaceuticals Inc.’s sector2025 Momentum Check & Free High Accuracy Swing Entry Alerts - خودرو بانک
What recovery options are there for Enanta Pharmaceuticals Inc.Market Risk Report & Community Trade Idea Sharing Platform - Newser
Can momentum traders help lift Enanta Pharmaceuticals Inc.2025 Sector Review & Consistent Profit Trading Strategies - Newser
Enanta Pharma (ENTA) Receives New 'Buy' Rating from WestPark Capital | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals: WestPark Capital initiates coverage with a Buy rating and $24 PT. - AInvest
Tools to monitor Enanta Pharmaceuticals Inc. recovery probabilityJuly 2025 Momentum & Accurate Trade Setup Notifications - Newser
How to manage a losing position in Enanta Pharmaceuticals Inc.2025 Price Action Summary & Community Driven Trade Alerts - Newser
Aug Chart Watch: Will Enanta Pharmaceuticals Inc. be affected by tariffsJuly 2025 Retail & Weekly High Return Forecasts - خودرو بانک
Can Enanta Pharmaceuticals Inc. rally from current levelsWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsWeekly Trade Report & Weekly High Potential Stock Alerts - Newser
Using data tools to time your Enanta Pharmaceuticals Inc. exit2025 Earnings Surprises & Fast Moving Market Watchlists - Newser
What MACD and RSI say about Enanta Pharmaceuticals Inc.2025 Sector Review & Safe Entry Zone Tips - Newser
Will Enanta Pharmaceuticals Inc. see short term momentumPortfolio Update Summary & Reliable Intraday Trade Plans - Newser
What recovery options are there for Enanta Pharmaceuticals IncJuly 2025 WrapUp & Fast Gain Stock Tips - Newser
How high can Enanta Pharmaceuticals Inc. stock goTrade Analysis Summary & Real-Time Price Movement Reports - Newser
Is a relief rally coming for Enanta Pharmaceuticals Inc. holdersTrade Signal Summary & Safe Entry Trade Signal Reports - Newser
Is Enanta Pharmaceuticals Inc. building a consolidation baseJuly 2025 Sector Moves & Stepwise Trade Execution Plans - Newser
Is Enanta Pharmaceuticals Inc. stock bottoming outJuly 2025 Breakouts & Reliable Trade Execution Plans - Newser
Applying Elliott Wave Theory to Enanta Pharmaceuticals Inc.Earnings Risk Report & Daily Growth Stock Tips - Newser
Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):